IL132310A0 - Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation - Google Patents

Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation

Info

Publication number
IL132310A0
IL132310A0 IL13231098A IL13231098A IL132310A0 IL 132310 A0 IL132310 A0 IL 132310A0 IL 13231098 A IL13231098 A IL 13231098A IL 13231098 A IL13231098 A IL 13231098A IL 132310 A0 IL132310 A0 IL 132310A0
Authority
IL
Israel
Prior art keywords
cells
activity
lymphocytic
inhibiting
cytomodulating
Prior art date
Application number
IL13231098A
Other languages
English (en)
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/028,083 external-priority patent/US6696545B1/en
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Publication of IL132310A0 publication Critical patent/IL132310A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL13231098A 1997-04-11 1998-04-10 Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation IL132310A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83891697A 1997-04-11 1997-04-11
US09/028,083 US6696545B1 (en) 1997-04-11 1998-02-23 Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
PCT/US1998/007231 WO1998046633A1 (fr) 1997-04-11 1998-04-10 Cytomodulation de peptides lipophiles aux fins d'une modulation de l'activite du systeme immunitaire et de la suppression de l'inflammation

Publications (1)

Publication Number Publication Date
IL132310A0 true IL132310A0 (en) 2001-03-19

Family

ID=26703275

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13231098A IL132310A0 (en) 1997-04-11 1998-04-10 Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation

Country Status (14)

Country Link
US (1) US7267822B2 (fr)
EP (1) EP0973799B1 (fr)
JP (1) JP4550171B2 (fr)
CN (1) CN1216900C (fr)
AT (1) ATE352556T1 (fr)
AU (2) AU761717B2 (fr)
BR (1) BR9808529B1 (fr)
CA (1) CA2286478A1 (fr)
IL (1) IL132310A0 (fr)
NO (1) NO994898L (fr)
NZ (1) NZ500287A (fr)
PL (1) PL336302A1 (fr)
TR (1) TR199902786T2 (fr)
WO (1) WO1998046633A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773240B1 (fr) 1997-12-30 2002-11-29 Synt Em Procede pour prevoir, identifier et decrire des molecules susceptibles de presenter un comportement recherche, notamment dans le domaine de la pharmacie et molecules obtenues par ce procede
WO2000063350A2 (fr) * 1999-04-21 2000-10-26 The University Of Georgia Research Foundation, Inc. Cysteine protease et inhibiteurs destines a la prevention et au traitement des neurocysterocoses
CA2474056A1 (fr) * 2002-01-24 2003-07-31 Sangstat Medical Corporation Therapie combinee pour le traitement d'infection vih
WO2003072061A2 (fr) * 2002-02-26 2003-09-04 Sangstat Medical Corporation Procedes et compositions pour traiter la toxicite gastro-intestinale induite par la therapie de cyto-ablation
FR2842738B1 (fr) * 2002-07-23 2006-02-10 Negma Lerads Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus
RU2005118425A (ru) * 2002-11-15 2006-02-10 Сэнгстат Медикал Корпорейшн (Us) Цитомодуляторные пептиды для лечения интерстициального цистита
WO2005001075A1 (fr) * 2003-05-15 2005-01-06 Sangstat Medical Corporation Compositions rdp58 et procedes de modulation de l'activite des osteoclastes et des osteoblastes
WO2005009457A1 (fr) * 2003-05-15 2005-02-03 Sangstat Medical Corporation Compositions de rdp58 et procedes d'inhibition de la vascularisation de populations de cellules
US7498309B2 (en) 2003-11-29 2009-03-03 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
CN104231054A (zh) * 2014-09-01 2014-12-24 王跃建 Il-10多肽抑制剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723128A (en) * 1987-01-30 1998-03-03 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic T-cell lymphocyte ("CTL") activity regulation by class I MHC peptides
AU619458B2 (en) 1987-01-30 1992-01-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte inhibition by hla peptides
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
US5385888A (en) * 1987-03-20 1995-01-31 The Regents Of The University Of California Class I MHC modulation or surface receptor activity
EP0459978B1 (fr) 1989-03-03 1997-07-16 The Regents Of The University Of California Modulation par le complexe majeur d'histocompatibilite (mhc) de classe i de l'activite du recepteur de surface
EP1018344A3 (fr) * 1991-08-26 2000-09-20 Epimmune, Inc. Epitopes du virus de l'hépatite B induisant une réponse CTL rétrécie par HLA
CA2122266A1 (fr) 1991-11-08 1993-05-13 Carol Clayberger Peptides se liant au domaine de liaison cd8
US5440015A (en) 1992-07-21 1995-08-08 Glycomed Incorporated Selectin peptide medicaments for treating disease
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
WO1995013288A1 (fr) * 1993-11-10 1995-05-18 The Board Of Trustees For The Leland Stanford Junior University Proteines de membrane de surface et leur effet sur la reponse immunitaire
WO1995023865A1 (fr) * 1994-03-03 1995-09-08 Genentech, Inc. Anticorps monoclonaux anti-il-8 pour le traitement des troubles
EP0804469B1 (fr) * 1995-01-16 2001-11-28 Northern Sydney Area Health Service Peptides ayant un effet sur les cellules T
US6162434A (en) * 1995-05-03 2000-12-19 Sangstat Medical Corporation Cytomodulating peptide for inhibiting lymphocyte activity
US5753625A (en) * 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease
WO1997024140A1 (fr) 1996-01-02 1997-07-10 The Board Of Trustees Of Leland Stanford Junior University Interaction de proteines hla avec des membres de la famille hsp70 de proteines
US6436903B1 (en) 1996-05-22 2002-08-20 Stanford University (Board Of Trustees Of The Leland Standford Junior University) Immunomodulating compounds comprising d-isomers of amino acids
AU3209897A (en) 1996-05-24 1997-12-09 Board Of Trustees Of The Leland Stanford Junior University Immunomodulating dimers
US6696545B1 (en) * 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation

Also Published As

Publication number Publication date
CN1259958A (zh) 2000-07-12
WO1998046633A1 (fr) 1998-10-22
AU2003244571B2 (en) 2007-07-05
TR199902786T2 (xx) 2000-06-21
BR9808529A (pt) 2000-10-24
EP0973799B1 (fr) 2007-01-24
EP0973799A1 (fr) 2000-01-26
AU6897898A (en) 1998-11-11
US7267822B2 (en) 2007-09-11
NO994898D0 (no) 1999-10-08
NZ500287A (en) 2002-10-25
AU761717B2 (en) 2003-06-05
BR9808529B1 (pt) 2010-10-05
PL336302A1 (en) 2000-06-19
ATE352556T1 (de) 2007-02-15
NO994898L (no) 1999-11-24
US20040248810A1 (en) 2004-12-09
AU2003244571A1 (en) 2003-10-02
JP4550171B2 (ja) 2010-09-22
CN1216900C (zh) 2005-08-31
JP2001526641A (ja) 2001-12-18
CA2286478A1 (fr) 1998-10-22

Similar Documents

Publication Publication Date Title
PL348147A1 (en) Utilisation of dialkylfumarates
TR199801168T2 (xx) �nterleukin-1 beta d�n��t�r�c� enzim inhibit�rleri.
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
AU1750097A (en) Highly concentrated, lyophilized, and liquid factor ix formulations
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
EA199700135A1 (ru) Ингибиторы клеточной адгезии
IL142905A0 (en) Functional antagonists of hedgehog activity
IL132310A0 (en) Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
AU5314900A (en) Compositions and methods for inhibiting cell death
WO1999045098A3 (fr) Apport de proteines a des cellules eucaryotes au moyen de la yersinia recombinee
ATE302848T1 (de) Stammzellen schutzfaktor und verwandte methoden und produkte
IT1299583B1 (it) Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
AU5168099A (en) Use of novel agents inducing cell death in synergy with interferons
WO1990007321A3 (fr) Sequences de guidage de recepteurs de lymphocytes et leurs emplois
AU6450098A (en) Butyrate prodrugs derived from lactic acid
PT1230261E (pt) Derivados nonapeptídicos de ny-eso-1 e suas utilizações
DK0925064T3 (da) 5-Androsten-3-beta,17-alpha-diol som inhibitor for tumorvækst
SE8701457D0 (sv) Immunostimulerande tripeptider
WO2000025763A3 (fr) Agents exerçant un effet inhibiteur de proliferation sur des cellules tumorales
Zaroukian SURFACE LY-5 GLYCOPROTEIN IN MURINE NATURAL KILLER (NK) CELL DEVELOPMENT, TARGET BINDING AND CYTOTOXICITY: FUNCTIONAL STUDIES AND PRELIMINARY BIOCHEMICAL CHARACTERIZATION.
Jespersen THE EFFECT OF ALPHA-FETOPROTEIN (AFP) AND OTHER CORD SERUM FRACTIONS ON MITOGEN-INDUCED LYMPHOCYTE TRANSFORMATION AND THE ONE-WAY MIXED LYMPHOCYTE REACTION.
Morris Collagenase and collagenase-inhibitory activity of rabbit articular chondrocytes in response to iron in cell culture.
NO910981L (no) Peptidforbindelser.
DE69916302D1 (de) Verwendung von dendritischen zellen-depletierten zusammensetzungen zur verbesserung der transplantation von allogenen hämatopoietischen zellen